glycine has been researched along with Amyloidosis in 13 studies
Amyloidosis: A group of sporadic, familial and/or inherited, degenerative, and infectious disease processes, linked by the common theme of abnormal protein folding and deposition of AMYLOID. As the amyloid deposits enlarge they displace normal tissue structures, causing disruption of function. Various signs and symptoms depend on the location and size of the deposits.
Excerpt | Relevance | Reference |
---|---|---|
"Bortezomib, a proteasome inhibitor (PI), has shown efficacy in the treatment of newly diagnosed and relapsed light chain (AL) amyloidosis, and is often used in combination with cyclophosphamide and dexamethasone." | 9.51 | Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis. ( Bergsagel, PL; Bradt, EE; Buadi, FK; Dingli, D; Dispenzieri, A; Fonder, A; Gertz, MA; Go, RS; Gonsalves, W; Hayman, SR; Helgeson, DK; Hobbs, M; Hwa, YL; Kapoor, P; Kourelis, TV; Kumar, SK; Lacy, MQ; LaPlant, BR; Larsen, JT; Leung, N; Muchtar, E; O'Brien, P; Rajkumar, SV; Siddiqui, M; Warsame, R, 2022) |
"This phase 1/2 study assessed the safety, tolerability, and preliminary efficacy of the oral proteasome inhibitor (PI) ixazomib in patients with relapsed/refractory immunoglobulin light chain (AL) amyloidosis." | 9.24 | A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. ( Berg, D; Cohen, AD; Comenzo, RL; Dispenzieri, A; Gupta, N; Hui, AM; Jaccard, A; Kukreti, V; Merlini, G; Palladini, G; Sanchorawala, V; Schönland, SO; Seldin, DC; Yang, H; Zonder, JA, 2017) |
"Bortezomib, a proteasome inhibitor (PI), has shown efficacy in the treatment of newly diagnosed and relapsed light chain (AL) amyloidosis, and is often used in combination with cyclophosphamide and dexamethasone." | 5.51 | Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis. ( Bergsagel, PL; Bradt, EE; Buadi, FK; Dingli, D; Dispenzieri, A; Fonder, A; Gertz, MA; Go, RS; Gonsalves, W; Hayman, SR; Helgeson, DK; Hobbs, M; Hwa, YL; Kapoor, P; Kourelis, TV; Kumar, SK; Lacy, MQ; LaPlant, BR; Larsen, JT; Leung, N; Muchtar, E; O'Brien, P; Rajkumar, SV; Siddiqui, M; Warsame, R, 2022) |
"This phase 1/2 study assessed the safety, tolerability, and preliminary efficacy of the oral proteasome inhibitor (PI) ixazomib in patients with relapsed/refractory immunoglobulin light chain (AL) amyloidosis." | 5.24 | A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. ( Berg, D; Cohen, AD; Comenzo, RL; Dispenzieri, A; Gupta, N; Hui, AM; Jaccard, A; Kukreti, V; Merlini, G; Palladini, G; Sanchorawala, V; Schönland, SO; Seldin, DC; Yang, H; Zonder, JA, 2017) |
" A kindred has been identified in which a glycine to arginine mutation at residue 26 in apoA-I is associated with hypoalphalipoproteinemia and hereditary systemic amyloidosis." | 3.68 | In vivo metabolism of a mutant apolipoprotein, apoA-IIowa, associated with hypoalphalipoproteinemia and hereditary systemic amyloidosis. ( Benson, MD; Brewer, HB; Gregg, RE; Meng, MS; Rader, DJ; Schaefer, JR; Zech, LA, 1992) |
"The association of multiple endocrine neoplasia type 2A with the dermatological disorder cutaneous lichen amyloidosis has already been reported, and mutations in the Cys634 have been identified in different families." | 1.30 | A Cys634Gly substitution of the RET proto-oncogene in a family with recurrence of multiple endocrine neoplasia type 2A and cutaneous lichen amyloidosis. ( Betsos, N; Camera, G; Celli, I; Claudiani, F; Romeo, G; Seri, M, 1997) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (15.38) | 18.7374 |
1990's | 4 (30.77) | 18.2507 |
2000's | 3 (23.08) | 29.6817 |
2010's | 2 (15.38) | 24.3611 |
2020's | 2 (15.38) | 2.80 |
Authors | Studies |
---|---|
Muchtar, E | 1 |
Gertz, MA | 1 |
LaPlant, BR | 1 |
Buadi, FK | 1 |
Leung, N | 1 |
O'Brien, P | 1 |
Bergsagel, PL | 1 |
Fonder, A | 1 |
Hwa, YL | 1 |
Hobbs, M | 1 |
Helgeson, DK | 1 |
Bradt, EE | 1 |
Gonsalves, W | 1 |
Lacy, MQ | 1 |
Kapoor, P | 1 |
Siddiqui, M | 1 |
Larsen, JT | 1 |
Warsame, R | 1 |
Hayman, SR | 1 |
Go, RS | 1 |
Dingli, D | 1 |
Kourelis, TV | 1 |
Dispenzieri, A | 2 |
Rajkumar, SV | 1 |
Kumar, SK | 1 |
Xing, Y | 1 |
Andrikopoulos, N | 1 |
Zhang, Z | 1 |
Sun, Y | 1 |
Ke, PC | 1 |
Ding, F | 1 |
Sanchorawala, V | 1 |
Palladini, G | 1 |
Kukreti, V | 1 |
Zonder, JA | 1 |
Cohen, AD | 1 |
Seldin, DC | 1 |
Jaccard, A | 1 |
Schönland, SO | 1 |
Berg, D | 1 |
Yang, H | 1 |
Gupta, N | 1 |
Hui, AM | 1 |
Comenzo, RL | 1 |
Merlini, G | 1 |
Maya-Martinez, R | 1 |
Gil-Rodriguez, P | 1 |
Amero, C | 1 |
Yazaki, M | 1 |
Varga, J | 1 |
Dyck, PJ | 1 |
Benson, MD | 2 |
De Carolis, P | 1 |
Galeotti, M | 1 |
Ficarra, G | 1 |
Masetti, M | 1 |
Grimaldi, D | 1 |
Cortelli, P | 1 |
Jacobson, DR | 1 |
Alves, IL | 1 |
Saraiva, MJ | 1 |
Thibodeau, SN | 1 |
Buxbaum, JN | 1 |
Dudek, SM | 1 |
Johnson, GV | 1 |
Seri, M | 1 |
Celli, I | 1 |
Betsos, N | 1 |
Claudiani, F | 1 |
Camera, G | 1 |
Romeo, G | 1 |
Akar, E | 1 |
Yalcinkaya, F | 1 |
Akar, N | 1 |
Bosseckert, H | 1 |
Rader, DJ | 1 |
Gregg, RE | 1 |
Meng, MS | 1 |
Schaefer, JR | 1 |
Zech, LA | 1 |
Brewer, HB | 1 |
Zuckerberg, A | 1 |
Gazith, J | 1 |
Rimon, A | 1 |
Reshef, T | 1 |
Gafni, J | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Phase 1/2 Trial of Ixazomib in Combination With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis[NCT01864018] | Phase 1/Phase 2 | 87 participants (Actual) | Interventional | 2013-08-20 | Active, not recruiting | ||
A Phase 3, Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physicians Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis[NCT01659658] | Phase 3 | 177 participants (Actual) | Interventional | 2012-12-12 | Terminated (stopped due to Sponsor's decision) | ||
An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Formulation of MLN9708 Administered Weekly in Adult Patients With Relapsed or Refractory Light-Chain (AL) Amyloidosis Who Require Further Treatment[NCT01318902] | Phase 1 | 27 participants (Actual) | Interventional | 2011-04-27 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Will be defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least 1/3 of patients, as assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. (NCT01864018)
Timeframe: At 28 days
Intervention | mg/m² weekly (Number) |
---|---|
Treatment (Ixazomib Citrate, Cyclophosphamide, Dexamethasone) | 400 |
The maximum grade for each type of adverse event will be recorded for each patient, and frequency tables will be reviewed to determine patterns. Additionally, the relationship of the adverse event(s) to the study treatment will be taken into consideration. Adverse events will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. A grade 3 event is one that is severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL. (NCT01864018)
Timeframe: Up to 5 years
Intervention | Participants (Count of Participants) |
---|---|
Phase I/II, Cohort A | 36 |
Phase II, Cohort B | 16 |
The percentage of successes will be estimated by the number of successes divided by the total number of evaluable patients. Exact binomial 95% confidence intervals for the true success proportion will be calculated. (NCT01864018)
Timeframe: Up to 48 weeks
Intervention | percentage of participants (Number) |
---|---|
Treatment (Ixazomib Citrate, Cyclophosphamide, Dexamethasone) | 35 |
The distribution of PFS will be estimated using the method of Kaplan Meier. (NCT01864018)
Timeframe: Time from registration to the earliest date of documentation of disease progression or death due to any cause, assessed up to 5 years
Intervention | months (Median) |
---|---|
Phase I/II, Cohort A | NA |
Phase II, Cohort B | NA |
The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients. Exact binomial 95% confidence intervals for the true success proportion will be calculated. (NCT01864018)
Timeframe: Up to 48 weeks
Intervention | percentage of participants (Number) |
---|---|
Treatment (Ixazomib Citrate, Cyclophosphamide, Dexamethasone) | 63 |
The distribution of survival time will be estimated using the method of Kaplan-Meier. (NCT01864018)
Timeframe: Time from registration to death due to any cause, assessed up to 5 years
Intervention | months (Median) |
---|---|
Phase I/II, Cohort A | NA |
Phase II, Cohort B | NA |
Will be defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least 1/3 of patients, as assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. (NCT01864018)
Timeframe: At 28 days
Intervention | mg weekly (Number) | |
---|---|---|
MTD of ixazomib | MTD of dexamethasone | |
Treatment (Ixazomib Citrate, Cyclophosphamide, Dexamethasone) | 4 | 40 |
Cardiac (Heart) deterioration was defined as the need for hospitalization for heart failure. Kidney deterioration was defined as progression to end-stage renal disease (ESRD) with the need for maintenance dialysis or renal transplantation. Vital organ deterioration was evaluated by an adjudication committee. Percentages were rounded off to the nearest decimal. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure. (NCT01659658)
Timeframe: Up to 2 years
Intervention | percentage of participants (Number) |
---|---|
Arm A: Ixazomib + Dexamethasone | 47 |
Arm B: Dexamethasone + Melphalan/Cyclophosphamide/Thalidomide/Lenalidomide | 54 |
SF-36 Version 2 is a multipurpose, participant completed, short-form health survey with 36 questions that consists of an 8-scale profile of functional health and well-being scores as well as psychometrically-based physical and mental health summary measures. Physical component summary (PCS) is mostly contributed by physical function (PF), role physical (RP), bodily pain (BP), and general health (GH). Mental component summary (MCS) is mostly contributed by mental health (MH), role emotional (RE), social function (SF), and vitality (VT). Each component on the SF-36 item health survey is scored from 0 (best) to 100 (worst). Total score ranges from 0-100, where higher scores are associated with less disability and better quality of life. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure. (NCT01659658)
Timeframe: Baseline, Week 28 of the PFS Follow-up
Intervention | score on a scale (Mean) |
---|---|
Arm B: Dexamethasone + Melphalan/Cyclophosphamide/Thalidomide/Lenalidomide | 2.0 |
The amyloidosis symptom scale questionnaire is a participant completed questionnaire that evaluates symptom severity of 3 symptoms: Swelling, Shortness of Breath and Dizziness, each rated on an 11-point scale where: 0=no symptoms to 10=very severe symptoms. Higher scores indicate worsening of symptoms. Total Score is the sum of all responses from the amyloidosis symptom scale ranging from 0 to 30. Higher scores represent higher levels of symptomatology or problems and a negative change from baseline indicates improvement. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure. (NCT01659658)
Timeframe: Baseline, Week 28 of the PFS Follow-up
Intervention | score on a scale (Mean) |
---|---|
Arm B: Dexamethasone + Melphalan/Cyclophosphamide/Thalidomide/Lenalidomide | -16.0 |
The FACT/GOG-Ntx is a participant completed questionnaire that comprises 11 individual items evaluating symptoms of neurotoxicity on a 5-point scale where: 0=not at all (best) to 4=very much for a total possible score of 0 to 44. Symptom scores are inverted so that higher scores of FACT/GOG-Ntx indicate higher quality of life or functioning. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure. (NCT01659658)
Timeframe: Baseline, Week 28 of the PFS Follow-up
Intervention | score on a scale (Mean) |
---|---|
Arm B: Dexamethasone + Melphalan/Cyclophosphamide/Thalidomide/Lenalidomide | 0.0 |
SF-36 Version 2 is a multipurpose, participant completed, short-form health survey with 36 questions that consists of an 8-scale profile of functional health and well-being scores as well as psychometrically-based physical and mental health summary measures. Physical component summary (PCS) is mostly contributed by physical function (PF), role physical (RP), bodily pain (BP), and general health (GH). Mental component summary (MCS) is mostly contributed by mental health (MH), role emotional (RE), social function (SF), and vitality (VT). Each component on the SF-36 item health survey is scored from 0 (best) to 100 (worst). Total score ranges from 0-100, where higher scores are associated with less disability and better quality of life. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure. (NCT01659658)
Timeframe: Baseline, Week 28 of the PFS Follow-up
Intervention | score on a scale (Mean) |
---|---|
Arm B: Dexamethasone + Melphalan/Cyclophosphamide/Thalidomide/Lenalidomide | 10.3 |
Duration of hematologic response (DOR) was defined as the time from the date of first documentation of a hematologic response to the date of first documented hematologic disease progression as determined by the investigator. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure. (NCT01659658)
Timeframe: From time of first documented response to disease progression (up to 115 months)
Intervention | months (Median) |
---|---|
Arm A: Ixazomib + Dexamethasone | NA |
Arm B: Dexamethasone + Melphalan/Cyclophosphamide/Thalidomide/Lenalidomide | 21.19 |
The EQ visual analogue scale (VAS) records the participant's self-rated health on a 20 centimeter vertical VAS that ranges from 0 (worst imaginable health state) to 100 (best imaginable health state). Baseline is defined as the value collected at the time closest to, but prior to, the start of study drug administration. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure. (NCT01659658)
Timeframe: At Week 28 of the OS follow-up
Intervention | score on a scale (Mean) |
---|---|
Arm B: Dexamethasone + Melphalan/Cyclophosphamide/Thalidomide/Lenalidomide | 23.0 |
Hematologic disease PFS was defined as the time from the date of randomization to the date of first documentation of hematologic PD according to central laboratory results and ISA criteria as evaluated by an adjudication committee, or death due to any cause, whichever occurred first. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure. (NCT01659658)
Timeframe: From first dose of study drug until discontinuation of study drug due to disease progression or unacceptable toxicity, or death whichever occurs first (up to 115 months)
Intervention | months (Median) |
---|---|
Arm A: Ixazomib + Dexamethasone | 29.50 |
Arm B: Dexamethasone + Melphalan/Cyclophosphamide/Thalidomide/Lenalidomide | 27.73 |
A hospitalization was defined as at least one overnight stay in an intensive care unit and/or non-intensive care unit. If a single hospitalization included both an intensive care unit stay and a non-intensive care unit stay, the hospitalization was counted only once (as an intensive care unit stay). The mean number of hospitalizations is reported in this outcome measure. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure. (NCT01659658)
Timeframe: From first dose of study drug until discontinuation of study drug due to disease progression or unacceptable toxicity, or death whichever occurs first (up to 115 months)
Intervention | hospitalizations (Mean) |
---|---|
Arm A: Ixazomib + Dexamethasone | 1.8 |
Arm B: Dexamethasone + Melphalan/Cyclophosphamide/Thalidomide/Lenalidomide | 1.4 |
A SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of an existing hospitalization, resulted in persistent or significant disability or incapacity, was a congenital anomaly/birth defect or medically important event. (NCT01659658)
Timeframe: From first dose of study drug through 30 days after administration of the last dose of study drug (up to 115 months)
Intervention | Participants (Count of Participants) |
---|---|
Arm A: Ixazomib + Dexamethasone | 44 |
Arm B: Dexamethasone + Melphalan | 11 |
Arm B: Dexamethasone + Cyclophosphamide | 2 |
Arm B: Dexamethasone + Thalidomide | 0 |
Arm B: Dexamethasone + Lenalidomide | 17 |
Overall survival was defined as the time from the date of randomization to the date of death. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure. (NCT01659658)
Timeframe: From first dose of study drug until discontinuation of study drug due to disease progression or unacceptable toxicity, or death whichever occurs first (up to 115 months)
Intervention | months (Median) |
---|---|
Arm A: Ixazomib + Dexamethasone | 69.55 |
Arm B: Dexamethasone + Melphalan/Cyclophosphamide/Thalidomide/Lenalidomide | 43.17 |
Vital organ (heart and kidney) response rate was defined as the percentage of participants who achieved vital organ response according to central laboratory results and ISA criteria as evaluated by an adjudication committee. A vital organ response was defined as response of 1 or 2 of the involved vital organs with no change from Baseline in the rest of involved vital organs. Percentages were rounded off to the nearest decimal. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure. (NCT01659658)
Timeframe: From first dose of study drug until discontinuation of study drug due to disease progression or unacceptable toxicity, or death whichever occurs first (up to 115 months)
Intervention | percentage of participants (Number) |
---|---|
Arm A: Ixazomib + Dexamethasone | 19 |
Arm B: Dexamethasone + Melphalan/Cyclophosphamide/Thalidomide/Lenalidomide | 12 |
Complete hematologic response was defined as the percentage of participants with CR based on central laboratory results and the 2010 ISA Consensus Criteria as assessed by the investigator. CR: Complete disappearance of M-protein from serum and urine on immunofixation, and normalization of FLC ratio. Percentages were rounded off to the nearest decimal. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure. (NCT01659658)
Timeframe: From first dose of study drug until discontinuation of study drug due to disease progression or unacceptable toxicity, or death whichever occurs first (up to 115 months)
Intervention | percentage of participants (Number) |
---|---|
Arm A: Ixazomib + Dexamethasone | 30 |
Arm B: Dexamethasone + Melphalan/Cyclophosphamide/Thalidomide/Lenalidomide | 17 |
Overall hematologic response was defined as the percentage of participants with complete response (CR), very good partial response (VGPR) and partial response (PR) based on central laboratory results and the 2010 International Society of Amyloidosis (ISA) Consensus Criteria as assessed by an adjudication committee. CR: Complete disappearance of M-protein from serum and urine on immunofixation, and normalization of free light chain (FLC) ratio. VGPR: differential free light chain (difference between involved and uninvolved FLC levels; dFLC) < 40 mg/L. PR: ≥50% reduction in dFLC. Percentages were rounded off to the nearest decimal. (NCT01659658)
Timeframe: From first dose of study drug until discontinuation of study drug due to disease progression or unacceptable toxicity, or death whichever occurs first (up to 115 months)
Intervention | percentage of participants (Number) |
---|---|
Arm A: Ixazomib + Dexamethasone | 53 |
Arm B: Dexamethasone + Melphalan | 58 |
Arm B: Dexamethasone + Cyclophosphamide | 30 |
Arm B: Dexamethasone + Thalidomide | 50 |
Arm B: Dexamethasone + Lenalidomide | 51 |
PFS was defined as the time from the date of randomization to the date of first documentation of hematologic disease progression, or organ (cardiac or renal) progression, or death due to any cause, whichever occurred first according to central laboratory results and ISA criteria as evaluated by the investigator. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure. (NCT01659658)
Timeframe: From first dose of study drug until discontinuation of study drug due to disease progression or unacceptable toxicity, or death whichever occurs first (up to 115 months)
Intervention | months (Median) |
---|---|
Arm A: Ixazomib + Dexamethasone | 11.86 |
Arm B: Dexamethasone + Melphalan/Cyclophosphamide/Thalidomide/Lenalidomide | 7.62 |
Time to subsequent anticancer therapy was defined as the time from randomization to the first date of subsequent anticancer therapy. Participants without subsequent anticancer therapy were censored at the date of death or last known to be alive. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure. (NCT01659658)
Timeframe: From first dose of study drug until subsequent anticancer treatment (up to 115 months)
Intervention | months (Median) |
---|---|
Arm A: Ixazomib + Dexamethasone | 26.48 |
Arm B: Dexamethasone + Melphalan/Cyclophosphamide/Thalidomide/Lenalidomide | 12.45 |
TTF was defined as the time from randomization to the date of first documented treatment failure. Treatment failure was defined as: 1) death due to any cause; 2) hematologic progression or major organ progression according to central laboratory results and ISA criteria as evaluated by the investigator; 3) clinically morbid organ disease requiring additional therapy; or 4) withdrawn for any reason. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure. (NCT01659658)
Timeframe: From first dose of study drug until discontinuation of study drug due to disease progression or unacceptable toxicity, or death whichever occurs first (up to 115 months)
Intervention | months (Median) |
---|---|
Arm A: Ixazomib + Dexamethasone | 10.32 |
Arm B: Dexamethasone + Melphalan/Cyclophosphamide/Thalidomide/Lenalidomide | 5.32 |
Time to vital organ deterioration or death was assessed by the investigator and defined as the time from randomization to vital organ (heart or kidney) deterioration or death, whichever occurs first. Cardiac deterioration is defined as the need for hospitalization for heart failure. Kidney deterioration is defined as progression to ESRD with the need for maintenance dialysis or renal transplantation. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure. (NCT01659658)
Timeframe: From randomization to time of vital organ deterioration or death (up to 115 months)
Intervention | months (Median) |
---|---|
Arm A: Ixazomib + Dexamethasone | 38.67 |
Arm B: Dexamethasone + Melphalan/Cyclophosphamide/Thalidomide/Lenalidomide | 26.09 |
Vital organ PFS is defined as the time from the date of randomization to the date of first documentation of progression of vital organ (heart or kidney) according to central laboratory results and ISA criteria as evaluated by an adjudication committee, or death due to any cause, whichever occurs first. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure. (NCT01659658)
Timeframe: From first dose of study drug until discontinuation of study drug due to disease progression or unacceptable toxicity, or death whichever occurs first (up to 115 months)
Intervention | months (Median) |
---|---|
Arm A: Ixazomib + Dexamethasone | 15.77 |
Arm B: Dexamethasone + Melphalan/Cyclophosphamide/Thalidomide/Lenalidomide | 11.01 |
The European Quality of Life (EuroQOL) 5-Dimensional (EQ-5D) is a patient completed questionnaire consisting of 2 pages: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). Each dimension has 3 possible choices: no problems to extreme problems. Higher scores=worsening of the quality of life. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure. (NCT01659658)
Timeframe: At Week 28 of the OS follow-up
Intervention | Participants (Count of Participants) | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mobility: No Problems in Walking About | Mobility: Some Problem in Walking About | Mobility: Confined to Bed | Self-Care: No Problems With Self- Care | Self-Care: Some Problems Washing or Dressing | Self-Care: Unable to Wash or Dress | Usual Activities: No Problems With Performing Usual Activities | Usual Activities: Some Problem With Performing Usual Activities | Usual Activities: Unable to Performing Usual Activities | Pain/Discomfort: No Pain or Discomfort | Pain/Discomfort: Moderate Pain or Discomfort | Pain/Discomfort: Extreme Pain or Discomfort | Anxiety/Depression: Not Anxious or Depressed | Anxiety/Depression: Moderately Anxious or Depressed | Anxiety/Depression: Extremely Anxious or Depressed | |
Arm A: Ixazomib + Dexamethasone | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Arm B: Dexamethasone + Melphalan/Cyclophosphamide/Thalidomide/Lenalidomide | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
As prespecified in the protocol, data for this outcome measure was planned to be collected for ixazomib arm group only. (NCT01659658)
Timeframe: Cycle 1, Day 1: 1, 4 hours postdose, Day 14: 144 hours postdose; Cycle 2, Day 1: predose, Day 14: 144 hours postdose; Cycles 3 to 10, Day 1: predose (cycle length=28 days)
Intervention | nanogram per milliliter (ng/mL) (Geometric Mean) | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cycle 1 Day 1: 1 Hour Post-dose | Cycle 1 Day 14: 4 Hours Post-dose | Cycle 1 Day 14: 144 Hours Post-dose | Cycle 2 Day 1: Pre-dose | Cycle 2 Day 14: 144 Hours Post-dose | Cycle 3 Day 1: Pre-dose | Cycle 4 Day 1 Pre-dose | Cycle 5 Day 1 Pre-dose | Cycle 6 Day 1: Pre-dose | Cycle 7 Day 1: Pre-dose | Cycle 8 Day 1: Pre-dose | Cycle 9 Day 1: Pre-dose | Cycle 10 Day 1: Pre-dose | |
Arm A: Ixazomib + Dexamethasone | 16.518 | 10.652 | 3.875 | 2.000 | 4.726 | 2.187 | 2.276 | 2.264 | 2.235 | 2.299 | 2.038 | 2.143 | 2.232 |
Duration of hematologic response, measured as the time from the date of first documentation of a hematologic response to the date of hematologic disease progression. (NCT01318902)
Timeframe: From the date of first documentation of a hematologic response to the date of hematologic disease progression (Up to approximately 12 months)
Intervention | months (Median) |
---|---|
Dose Escalation Cohort: Ixazomib 4.0 mg | 12.9 |
Dose Expansion Cohort: Ixazomib 4.0 mg (PI Naive) | 69.5 |
Dose Expansion Cohort: Ixazomib 4.0 mg (PI Exposed) | 19.7 |
Duration of organ response, measured as the time from the date of first documentation of a organ response to the date of organ disease progression. (NCT01318902)
Timeframe: From the date of first documentation of a organ response to the date of organ disease progression (Up to approximately 12 months)
Intervention | months (Median) |
---|---|
Dose Escalation Cohort: Ixazomib 4.0 mg | 4.1 |
Dose Expansion Cohort: Ixazomib 4.0 mg (PI Naive) | 20.5 |
Dose Expansion Cohort: Ixazomib 4.0 mg (PI Exposed) | 18.25 |
Hematologic disease PFS, measured as the time from the date of the first dose of ixazomib to the date of hematologic disease progression or death. (NCT01318902)
Timeframe: From the date of the first dose of ixazomib to the date of hematologic disease progression or death (Up to approximately 12 months)
Intervention | months (Median) |
---|---|
Dose Escalation Cohort: Ixazomib 4.0 mg | 14.8 |
Dose Escalation Cohort: Ixazomib 5.5 mg | 7.2 |
Dose Expansion Cohort: Ixazomib 4.0 mg (PI Naive) | 73.0 |
Dose Expansion Cohort: Ixazomib 4.0 mg (PI Exposed) | 8.3 |
MTD was highest dose of Ixazomib, at which <=1 of 6 participants experienced dose-limiting toxicity (DLT). DLT was defined using National Cancer Institute Common Terminology Criteria for Adverse Events, v 4.03 as: Grade 4 neutropenia (absolute neutrophil count <500 cells/mm^3) for >7 days;Grade 3 neutropenia with fever or infection;Grade 4 thrombocytopenia (platelets < 25,000/mm^3) for >7 days;Grade 3 thrombocytopenia with clinically significant bleeding;platelet count <10,000/mm^3;Grade 2 peripheral neuropathy with pain or >=Grade 3 peripheral neuropathy; >=Grade 3 nausea/emesis, diarrhea controlled by supportive therapy;Grade 3 QTc prolongation (QTc >500 msec);any >=Grade 3 nonhematologic toxicity except Grade 3 arthralgia/myalgia;or <1 week Grade 3 fatigue;delay in initiation of the subsequent therapy cycle by >2 weeks;other >=Grade 2 study drug-related nonhematologic toxicities requiring therapy discontinuation, considered possibly related to therapy as assessed by Investigator. (NCT01318902)
Timeframe: Cycle 1 (28 days)
Intervention | mg (Number) |
---|---|
Dose Escalation Cohort: Ixazomib 4.0 mg | 4 |
Dose Escalation Cohort: Ixazomib 5.5 mg | 4 |
The overall hematologic response rate is defined as number of participants with complete response (CR) or partial response (PR) or very good partial response (VGPR) as assessed by the investigator. Response is determined according to standardized criteria using a central laboratory. CR=serum and urine negative for monoclonal protein by immunofixation; or free light chain ratio normal; < 5% plasma cells in bone marrow without clonal dominance. PR=reduction in dFLC > 50%. VGPR= dFLC < 40 mg/L. (NCT01318902)
Timeframe: Day 22 to 28 in each cycle and end of treatment visit; then every 6 weeks thereafter until disease progression or initiation of subsequent antineoplastic therapy (Up to approximately 12 months)
Intervention | Participants (Count of Participants) |
---|---|
Dose Escalation Cohort: Ixazomib 4.0 mg | 4 |
Dose Escalation Cohort: Ixazomib 5.5 mg | 0 |
Dose Expansion Cohort: Ixazomib 4.0 mg (PI Naive) | 4 |
Dose Expansion Cohort: Ixazomib 4.0 mg (PI Exposed) | 3 |
Organ response rate was estimated as the number of participants with documented organ response (ie. Heart or kidney ). Treatment response of amyloid-related organs were identified based on national cancer institute, common terminology criteria for adverse events (NCI CTCAE) Version 4.02 criteria. (NCT01318902)
Timeframe: At Cycles 3, 6, 9, and 12; every 6 months thereafter until disease progression or the initiation of subsequent antineoplastic therapy and at end of treatment (EOT) visit (Up to approximately 12 months)
Intervention | Participants (Count of Participants) |
---|---|
Dose Escalation Cohort: Ixazomib 4.0 mg | 2 |
Dose Escalation Cohort: Ixazomib 5.5 mg | 0 |
Dose Expansion Cohort: Ixazomib 4.0 mg (PI Naive) | 2 |
Dose Expansion Cohort: Ixazomib 4.0 mg (PI Exposed) | 2 |
Organ disease PFS, measured as the time from the date of the first dose of ixazomib to the date of organ disease progression or death. (NCT01318902)
Timeframe: From the date of the first dose of ixazomib to the date of organ disease progression or death (Up to approximately 12 months)
Intervention | months (Median) |
---|---|
Dose Escalation Cohort: Ixazomib 4.0 mg | NA |
Dose Escalation Cohort: Ixazomib 5.5 mg | NA |
Dose Expansion Cohort: Ixazomib 4.0 mg (PI Naive) | NA |
Dose Expansion Cohort: Ixazomib 4.0 mg (PI Exposed) | NA |
One-year survival, defined as the patient survival probability at 1 year after the date of first dose of ixazomib. (NCT01318902)
Timeframe: From the date of the first dose of ixazomib to the date of hematologic disease progression or death (Up to 1 year)
Intervention | percentage of participants (Number) |
---|---|
Dose Escalation Cohort: Ixazomib 4.0 mg | 83.3 |
Dose Expansion Cohort: Ixazomib 4.0 mg (PI Naive) | 80.0 |
Dose Expansion Cohort: Ixazomib 4.0 mg (PI Exposed) | 21.5 |
The RP2D is the maximum tolerated dose (MTD) or less. The MTD is defined as the dose range at which ≤ 1 of 6 evaluable participants experience dose limiting toxicities (DLT) within the first 28 days of treatment (end of Cycle 1). The RP2D of Ixazomib was determined in dose escalation group on the basis of the totality of safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) data observed in Cycle 1. (NCT01318902)
Timeframe: Cycle 1 (28 days)
Intervention | mg (Number) |
---|---|
Dose Escalation Cohort: Ixazomib 4.0 mg | 4 |
Dose Escalation Cohort: Ixazomib 5.5 mg | 4 |
Time to first hematologic response, measured as the time from the first dose of ixazomib to the date of first documentation of a hematologic response. (NCT01318902)
Timeframe: From the date of the first dose of ixazomib to the date of first documentation of a hematologic response (Up to approximately 12 months)
Intervention | months (Median) |
---|---|
Dose Escalation Cohort: Ixazomib 4.0 mg | 0.79 |
Dose Expansion Cohort: Ixazomib 4.0 mg (PI Naive) | 3.45 |
Dose Expansion Cohort: Ixazomib 4.0 mg (PI Exposed) | 2.11 |
Time to first organ response, measured as the time from the first dose of ixazomib to the date of first documentation of a organ response. (NCT01318902)
Timeframe: From the date of the first dose of ixazomib to the date of first documentation of a organ response (Up to approximately 12 months)
Intervention | months (Median) |
---|---|
Dose Escalation Cohort: Ixazomib 4.0 mg | 6.85 |
Dose Expansion Cohort: Ixazomib 4.0 mg (PI Naive) | 9.55 |
Dose Expansion Cohort: Ixazomib 4.0 mg (PI Exposed) | 6.85 |
Time to hematologic progression, measured as the time from the date of the first dose of ixazomib to the date of first documented hematologic disease progression. (NCT01318902)
Timeframe: From the date of the first dose of ixazomib to the date of first documented hematologic disease progression (Up to approximately 12 months)
Intervention | months (Median) |
---|---|
Dose Escalation Cohort: Ixazomib 4.0 mg | 14.8 |
Dose Escalation Cohort: Ixazomib 5.5 mg | NA |
Dose Expansion Cohort: Ixazomib 4.0 mg (PI Naive) | 73.0 |
Dose Expansion Cohort: Ixazomib 4.0 mg (PI Exposed) | 8.3 |
Time to organ disease progression, measured as the time from the date of the first dose of ixazomib to the date of first documented organ disease progression. (NCT01318902)
Timeframe: From the date of the first dose of ixazomib to the date of first documented organ disease progression (Up to approximately 12 months)
Intervention | months (Median) |
---|---|
Dose Escalation Cohort: Ixazomib 4.0 mg | 11 |
Dose Expansion Cohort: Ixazomib 4.0 mg (PI Naive) | 12.85 |
Dose Expansion Cohort: Ixazomib 4.0 mg (PI Exposed) | 25.15 |
(NCT01318902)
Timeframe: Cycle 1: Day 1 (MTD cohort participants only, 4.0 mg) and Day 15 (all participants enrolled in the study): predose (within 1 hour (hr) before dosing), and postdose at multiple timepoints up to 168 hr
Intervention | hr*ng/mL (Mean) |
---|---|
Cycle 1, Day 15 | |
Ixazomib 5.5 mg | 1725.0 |
(NCT01318902)
Timeframe: Cycle 1: Day 1 (MTD cohort participants only, 4.0 mg) and Day 15 (all participants enrolled in the study): predose (within 1 hour (hr) before dosing), and postdose at multiple timepoints up to 168 hr
Intervention | hr*ng/mL (Mean) | |
---|---|---|
Cycle 1, Day 1 | Cycle 1, Day 15 | |
Ixazomib 4.0 mg | 861.0 | 1078.1 |
(NCT01318902)
Timeframe: Cycle 1: Day 1 (MTD cohort participants only, 4.0 mg) and Day 15 (all participants enrolled in the study): predose (within 1 hour (hr) before dosing), and postdose at multiple timepoints up to 168 hr
Intervention | hr*percentage of inhibition (Mean) | |
---|---|---|
Cycle 1, Day 1 | Cycle 1, Day 15 | |
Ixazomib 4.0 mg | 3333.6 | 3943.0 |
(NCT01318902)
Timeframe: Cycle 1: Day 1 (MTD cohort participants only, 4.0 mg) and Day 15 (all participants enrolled in the study): predose (within 1 hour (hr) before dosing), and postdose at multiple timepoints up to 168 hr
Intervention | ng/mL (Mean) |
---|---|
Cycle 1, Day 15 | |
Ixazomib 5.5 mg | 92.20 |
(NCT01318902)
Timeframe: Cycle 1: Day 1 (MTD cohort participants only, 4.0 mg) and Day 15 (all participants enrolled in the study): predose (within 1 hour (hr) before dosing), and postdose at multiple timepoints up to 168 hr
Intervention | ng/mL (Mean) | |
---|---|---|
Cycle 1, Day 1 | Cycle 1, Day 15 | |
Ixazomib 4.0 mg | 54.00 | 51.26 |
(NCT01318902)
Timeframe: Cycle 1: Day 1 (MTD cohort participants only, 4.0 mg) and Day 15 (all participants enrolled in the study): predose (within 1 hour (hr) before dosing), and postdose at multiple timepoints up to 168 hr
Intervention | ng/mL (Mean) |
---|---|
Cycle 1, Day 15 | |
Ixazomib 5.5 mg | 5.3300 |
(NCT01318902)
Timeframe: Cycle 1: Day 1 (MTD cohort participants only, 4.0 mg) and Day 15 (all participants enrolled in the study): predose (within 1 hour (hr) before dosing), and postdose at multiple timepoints up to 168 hr
Intervention | ng/mL (Mean) | |
---|---|---|
Cycle 1, Day 1 | Cycle 1, Day 15 | |
Ixazomib 4.0 mg | 2.1539 | 2.9140 |
(NCT01318902)
Timeframe: Cycle 1: Day 1 (MTD cohort participants only, 4.0 mg) and Day 15 (all participants enrolled in the study): predose (within 1 hour (hr) before dosing), and postdose at multiple timepoints up to 168 hr
Intervention | percentage of inhibition (Mean) | |
---|---|---|
Cycle 1, Day 1 | Cycle 1, Day 15 | |
Ixazomib 4.0 mg | 54.10 | 61.09 |
An AE is any untoward medical occurrence in a participant administered a medicinal investigational drug. The untoward medical occurrence does not necessarily have to have a causal relationship with treatment. An SAE is any untoward medical occurrence that results in death; is life-threatening; requires inpatient hospitalization or prolongation of present hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect or is a medically important event that may not be immediately life-threatening or result in death or hospitalization, but may jeopardize the participant or may require intervention to prevent one of other outcomes listed in definition above, or involves suspected transmission via a medicinal product of an infectious agent. A TEAE is defined as an AE that occurs after administration of first dose of study drug and through 30 days after last dose of study drug or until start of subsequent antineoplastic therapy. (NCT01318902)
Timeframe: From the first dose of study drug plus 30 days after last dose of study drug or until the initiation of subsequent antineoplastic therapy (Up to approximately 13 months)
Intervention | Participants (Count of Participants) | |
---|---|---|
TEAE | SAE | |
Dose Escalation Cohort: Ixazomib 4.0 mg | 6 | 3 |
Dose Escalation Cohort: Ixazomib 5.5 mg | 5 | 5 |
Dose Expansion Cohort: Ixazomib 4.0 mg (PI Exposed) | 10 | 5 |
Dose Expansion Cohort: Ixazomib 4.0 mg (PI Naive) | 5 | 5 |
The number of participants with any clinically significant abnormal standard safety laboratory values collected throughout the study reported as TEAEs. Parameters assessed were hematology, serum chemistry and urinalysis. Abnormal laboratory values were assessed as an AE if that value leads to discontinuation or delay in treatment, dose modification, therapeutic intervention, or is considered by the investigator to be a clinically significant change from baseline. (NCT01318902)
Timeframe: From the first dose of study drug plus 30 days after last dose of study drug or until the initiation of subsequent antineoplastic therapy (Up to approximately 13 months)
Intervention | Participants (Count of Participants) | ||||||
---|---|---|---|---|---|---|---|
Thrombocytopenia | Anaemia | Neutropenia | Hyponatraemia | Hypokalaemia | Blood creatinine increased | Platelet count decreased | |
Dose Escalation Cohort: Ixazomib 4.0 mg | 2 | 2 | 0 | 1 | 1 | 1 | 0 |
Dose Escalation Cohort: Ixazomib 5.5 mg | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
Dose Expansion Cohort: Ixazomib 4.0 mg (PI Exposed) | 2 | 0 | 1 | 1 | 1 | 1 | 0 |
Dose Expansion Cohort: Ixazomib 4.0 mg (PI Naive) | 2 | 2 | 0 | 1 | 0 | 0 | 0 |
Neurotoxicity was assessed as the number of participants with the TEAE of peripheral neuropathy. (NCT01318902)
Timeframe: From the first dose of study drug plus 30 days after last dose of study drug or until the initiation of subsequent antineoplastic therapy (Up to approximately 13 months)
Intervention | Participants (Count of Participants) | |
---|---|---|
Peripheral sensory neuropathy | Neuropathy peripheral | |
Dose Escalation Cohort: Ixazomib 4.0 mg | 1 | 1 |
Dose Escalation Cohort: Ixazomib 5.5 mg | 0 | 0 |
Dose Expansion Cohort: Ixazomib 4.0 mg (PI Exposed) | 1 | 0 |
Dose Expansion Cohort: Ixazomib 4.0 mg (PI Naive) | 1 | 0 |
(NCT01318902)
Timeframe: Cycle 1: Day 1 (MTD cohort participants only, 4.0 mg) and Day 15 (all participants enrolled in the study): predose (within 1 hour (hr) before dosing), and postdose at multiple timepoints up to 168 hr
Intervention | hours (Median) | |
---|---|---|
Cycle 1, Day 1 | Cycle 1, Day 15 | |
Ixazomib 4.0 mg | 1.0000 | 1.0300 |
(NCT01318902)
Timeframe: Cycle 1: Day 1 (MTD cohort participants only, 4.0 mg) and Day 15 (all participants enrolled in the study): predose (within 1 hour (hr) before dosing), and postdose at multiple timepoints up to 168 hr
Intervention | hours (Median) |
---|---|
Cycle 1, Day 15 | |
Ixazomib 5.5 mg | 0.7500 |
(NCT01318902)
Timeframe: Cycle 1: Day 1 (MTD cohort participants only, 4.0 mg) and Day 15 (all participants enrolled in the study): predose (within 1 hour (hr) before dosing), and postdose at multiple timepoints up to 168 hr
Intervention | hours (Median) | |
---|---|---|
Cycle 1, Day 1 | Cycle 1, Day 15 | |
Ixazomib 4.0 mg | 1.0000 | 1.0000 |
2 trials available for glycine and Amyloidosis
Article | Year |
---|---|
Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis.
Topics: Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Cycl | 2022 |
A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.
Topics: Administration, Oral; Aged; Amyloidosis; Boron Compounds; Disease-Free Survival; Female; Follow-Up S | 2017 |
A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.
Topics: Administration, Oral; Aged; Amyloidosis; Boron Compounds; Disease-Free Survival; Female; Follow-Up S | 2017 |
A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.
Topics: Administration, Oral; Aged; Amyloidosis; Boron Compounds; Disease-Free Survival; Female; Follow-Up S | 2017 |
A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.
Topics: Administration, Oral; Aged; Amyloidosis; Boron Compounds; Disease-Free Survival; Female; Follow-Up S | 2017 |
11 other studies available for glycine and Amyloidosis
Article | Year |
---|---|
Modulating Nanodroplet Formation En Route to Fibrillization of Amyloid Peptides with Designed Flanking Sequences.
Topics: Amyloid; Amyloid beta-Peptides; Amyloidosis; Glycine; Humans; Nanostructures; Serine | 2022 |
Solution structure of 6aJL2 and 6aJL2-R24G amyloidogenics light chain proteins.
Topics: Amino Acid Sequence; Amyloid; Amyloidosis; Arginine; Entropy; Glycine; Humans; Immunoglobulin lambda | 2015 |
A new transthyretin variant Leu55Gln in a patient with systemic amyloidosis.
Topics: Amyloidosis; Female; Glycine; Humans; Leucine; Middle Aged; Mutation; Polymorphism, Restriction Frag | 2002 |
Fatal cerebral haemorrhage after liver transplantation in a patient with transthyretin variant (gly53glu) amyloidosis.
Topics: Adult; Amyloidosis; Cerebral Hemorrhage; Glutamic Acid; Glycine; Humans; Liver Transplantation; Male | 2006 |
Transthyretin Ser 6 gene frequency in individuals without amyloidosis.
Topics: Amyloidosis; Founder Effect; Gene Frequency; Glycine; Humans; Point Mutation; Polymorphism, Genetic; | 1995 |
Transglutaminase facilitates the formation of polymers of the beta-amyloid peptide.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloidosis; Glycine; Humans; Lysine; Mutation; Transgluta | 1994 |
A Cys634Gly substitution of the RET proto-oncogene in a family with recurrence of multiple endocrine neoplasia type 2A and cutaneous lichen amyloidosis.
Topics: Adolescent; Adult; Amyloidosis; Child; Cysteine; Deoxyribonucleases, Type II Site-Specific; Drosophi | 1997 |
Is the Ala138Gly alteration of MEFV gene important for amyloidosis?
Topics: Alanine; Amino Acid Substitution; Amyloidosis; Cytoskeletal Proteins; Familial Mediterranean Fever; | 2001 |
[Gastroenterologic diseases and their relationship to the urogenital system].
Topics: Amyloidosis; Bile Acids and Salts; Celiac Disease; Cholelithiasis; Cholestyramine Resin; Colitis, Ul | 1978 |
In vivo metabolism of a mutant apolipoprotein, apoA-IIowa, associated with hypoalphalipoproteinemia and hereditary systemic amyloidosis.
Topics: Adult; Amyloidosis; Apolipoprotein A-I; Arginine; Electrophoresis, Gel, Two-Dimensional; Female; Gly | 1992 |
The structural subunit of amyloid. Isolation and characterization of a polypeptide capable of fibril formation.
Topics: Amino Acids; Amyloid; Amyloidosis; Birefringence; Carbohydrates; Chromatography, Thin Layer; Congo R | 1972 |